HUE048478T2 - NGF antagonista doménból és TNFalfa antagonista doménból álló kiméra protein - Google Patents
NGF antagonista doménból és TNFalfa antagonista doménból álló kiméra proteinInfo
- Publication number
- HUE048478T2 HUE048478T2 HUE15701985A HUE15701985A HUE048478T2 HU E048478 T2 HUE048478 T2 HU E048478T2 HU E15701985 A HUE15701985 A HU E15701985A HU E15701985 A HUE15701985 A HU E15701985A HU E048478 T2 HUE048478 T2 HU E048478T2
- Authority
- HU
- Hungary
- Prior art keywords
- antagonist domain
- chimeric protein
- tnfalpha
- protein consisting
- ngf
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461934828P | 2014-02-02 | 2014-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE048478T2 true HUE048478T2 (hu) | 2020-08-28 |
Family
ID=52440681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15701985A HUE048478T2 (hu) | 2014-02-02 | 2015-02-02 | NGF antagonista doménból és TNFalfa antagonista doménból álló kiméra protein |
Country Status (21)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2938066C (en) | 2014-02-02 | 2025-05-06 | Medimmune Limited | CHIMERIC PROTEIN COMPOSED OF NERVE GROWTH FACTOR ANTAGONIST DOMAIN AND TUMOR NECROSIS FACTOR-ANTAGONIST DOMAIN-A |
| US9862760B2 (en) * | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| SG11202001772SA (en) | 2017-09-21 | 2020-04-29 | Merck Patent Gmbh | Fusion protein comprising an fgf-18 moiety |
| WO2021142573A1 (zh) * | 2020-01-13 | 2021-07-22 | 丁邦 | 一种融合蛋白及其制法和用途 |
| KR20230084199A (ko) * | 2020-09-28 | 2023-06-12 | 메디뮨 리미티드 | 통증 치료를 위한 화합물 및 방법 |
| CN114574444B (zh) * | 2020-12-01 | 2024-05-03 | 达达生物技术(北京)有限公司 | 自体纤维母细胞在制备抗类风湿关节炎药物中的应用 |
| TWI821881B (zh) * | 2021-01-29 | 2023-11-11 | 醫研生物科技有限公司 | 腫瘤壞死因子α重組抗體及其用途 |
| CN116179667A (zh) * | 2022-09-21 | 2023-05-30 | 福建中妆技术研究有限公司 | 基于斑马鱼模型中trpv1信号通路筛选皮肤疼痛舒缓原料的试剂盒及应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE10399023I2 (de) | 1989-09-12 | 2006-11-23 | Ahp Mfg B V | TFN-bindende Proteine |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| JP2002508933A (ja) * | 1997-12-24 | 2002-03-26 | ダイアテック・ピーティワイ・リミテッド | 二官能分子 |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| DE19926068C1 (de) * | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| CN1684708A (zh) | 2001-05-30 | 2005-10-19 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| ZA200502612B (en) | 2002-10-08 | 2007-07-25 | Rinat Neuroscience Corp | Methods for treating post-surgical pain by administering a nerve crowth factor antagonist and compositions containing the same |
| US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| WO2005075514A2 (en) | 2004-03-10 | 2005-08-18 | Lonza Ltd. | Method for producing antibodies |
| WO2006024497A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| RU2406728C2 (ru) | 2005-01-24 | 2010-12-20 | Медиммун Лимитэд | Партнеры специфического связывания с ngf |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| MX2009012343A (es) * | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| WO2009092014A1 (en) | 2008-01-18 | 2009-07-23 | Gagnon Peter S | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| MX2010014574A (es) * | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
| JP2011016676A (ja) * | 2009-07-07 | 2011-01-27 | Sumitomo Electric Ind Ltd | 窒化物半導体基板の製造方法 |
| AR078651A1 (es) * | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| RU2012127383A (ru) | 2009-12-02 | 2014-01-10 | Акселерон Фарма Инк. | Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке |
| JP2013523153A (ja) * | 2010-04-07 | 2013-06-17 | アッヴィ・インコーポレイテッド | ＴＮＦ−α結合タンパク質 |
| DK2714738T3 (en) * | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| CA2854806A1 (en) | 2011-11-07 | 2013-05-16 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
| US20130171059A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| WO2014106001A2 (en) * | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | Dual specific binding proteins having a receptor sequence |
| RU2015143833A (ru) | 2013-03-15 | 2017-04-21 | Эббви Инк. | СВЯЗЫВАЮЩИЕ БЕЛКИ С ДВОЙНОЙ СПЕЦИФИЧНОСТЬЮ, НАПРАВЛЕННЫЕ ПРОТИВ TNFα |
| CA2938066C (en) | 2014-02-02 | 2025-05-06 | Medimmune Limited | CHIMERIC PROTEIN COMPOSED OF NERVE GROWTH FACTOR ANTAGONIST DOMAIN AND TUMOR NECROSIS FACTOR-ANTAGONIST DOMAIN-A |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US20210009671A1 (en) | 2019-05-10 | 2021-01-14 | Medimmune Limited | Compounds and methods for treating pain |
-
2015
- 2015-02-02 CA CA2938066A patent/CA2938066C/en active Active
- 2015-02-02 PL PL15701985T patent/PL3099713T3/pl unknown
- 2015-02-02 MX MX2016010030A patent/MX382763B/es unknown
- 2015-02-02 ES ES15701985T patent/ES2784238T3/es active Active
- 2015-02-02 RU RU2016132370A patent/RU2678810C2/ru active
- 2015-02-02 EP EP15701985.2A patent/EP3099713B1/en active Active
- 2015-02-02 US US14/612,137 patent/US9884911B2/en active Active
- 2015-02-02 RS RS20200396A patent/RS60156B1/sr unknown
- 2015-02-02 SI SI201531149T patent/SI3099713T1/sl unknown
- 2015-02-02 DK DK15701985.2T patent/DK3099713T3/da active
- 2015-02-02 PT PT157019852T patent/PT3099713T/pt unknown
- 2015-02-02 WO PCT/EP2015/052098 patent/WO2015114150A1/en not_active Ceased
- 2015-02-02 AU AU2015212787A patent/AU2015212787B2/en active Active
- 2015-02-02 SM SM20200182T patent/SMT202000182T1/it unknown
- 2015-02-02 CN CN202311359790.8A patent/CN118085103A/zh active Pending
- 2015-02-02 CN CN201580017113.5A patent/CN106459190A/zh active Pending
- 2015-02-02 JP JP2016549449A patent/JP6687526B2/ja active Active
- 2015-02-02 HR HRP20200477TT patent/HRP20200477T1/hr unknown
- 2015-02-02 LT LTEP15701985.2T patent/LT3099713T/lt unknown
- 2015-02-02 KR KR1020167023831A patent/KR102489452B1/ko active Active
- 2015-02-02 EP EP19214210.7A patent/EP3696193A1/en active Pending
- 2015-02-02 HU HUE15701985A patent/HUE048478T2/hu unknown
-
2017
- 2017-12-21 US US15/849,771 patent/US10457728B2/en active Active
-
2019
- 2019-09-17 US US16/573,192 patent/US11053307B2/en active Active
-
2020
- 2020-04-01 JP JP2020065513A patent/JP7074792B2/ja active Active
- 2020-04-10 CY CY20201100338T patent/CY1123248T1/el unknown
- 2020-09-11 AU AU2020230316A patent/AU2020230316B2/en active Active
-
2021
- 2021-05-28 US US17/333,291 patent/US11897949B2/en active Active
-
2022
- 2022-05-11 JP JP2022077858A patent/JP7520070B2/ja active Active
-
2023
- 2023-12-21 AU AU2023285832A patent/AU2023285832A1/en active Pending
-
2024
- 2024-01-03 US US18/403,043 patent/US20240262902A1/en active Pending
- 2024-07-08 JP JP2024109298A patent/JP2024133644A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281819A (en) | Chimeric antigen receptors and methods of making | |
| IL262041A (en) | Chimeric receptors and methods of use thereof | |
| IL282048A (en) | Oxysterols and methods of use thereof | |
| IL254068A0 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
| IL251970B (en) | Anti-cd79b antibodies and methods of use | |
| PL3148579T3 (pl) | Przeciwciała anty-gitr i sposoby ich zastosowania | |
| PT3368534T (pt) | Ditosilato de valbenazina e polimorfos do mesmo | |
| PL3157552T3 (pl) | Polipeptydy syntac i ich zastosowania | |
| PT3350220T (pt) | Anticorpos anti-pró-miostatina/miostatina latente e suas utilizações | |
| LT3295951T (lt) | Anti-pvrig antikūnai ir naudojimo būdai | |
| DK3229838T3 (da) | Anti-C10orf54-antistoffer og anvendelser deraf | |
| DK3126388T3 (da) | Anti-EGFRvIII-antistoffer og anvendelser deraf | |
| MA40933A (fr) | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines | |
| DK3132517T3 (da) | Frekvenssvar | |
| HUE048478T2 (hu) | NGF antagonista doménból és TNFalfa antagonista doménból álló kiméra protein | |
| EP3191599C0 (en) | DETECTION OF MISFOLDED PROTEINS | |
| EP3326560A4 (en) | ULTRASOUND PROBE | |
| IL272851A (en) | Methods of using dipivefrin | |
| DK3217856T3 (da) | Hulsonde med manchet | |
| EP3879472C0 (en) | COMPARISON AND SIMULATION OF WASHES FOR CIP | |
| DK3364189T3 (da) | Immunkromatografisk teststykke | |
| DK3184633T3 (da) | Modificeret beta-galaktosidase | |
| HRP20182029T1 (hr) | Uti-fuzijski proteini | |
| EP3470927A4 (en) | TONER | |
| EP3421989A4 (en) | Test method |